## **Product** Data Sheet

## **IV-23**

 Cat. No.:
 HY-126324

 CAS No.:
 2326007-49-0

 Molecular Formula:
 C<sub>18</sub>H<sub>18</sub>BrNO<sub>4</sub>

Molecular Weight: 392.24

Target: Apoptosis
Pathway: Apoptosis

**Storage:** Please store the product under the recommended conditions in the Certificate of

Analysis.

## **BIOLOGICAL ACTIVITY**

Description	IV-23 (Compound 20) is a potent Noxa mediated apoptosis inducer, and it is a promising anticancer agent with potential. IV-23 inhibits cell growths in vitro and in vivo, reduces colony formation, arrests cell cycle at M phase, and induces esophageal squamous cell carcinoma (ESCC) <sup>[1]</sup> .
In Vitro	IV-23 (Compound 20) shows a strong inhibition against the ESCCs in a concentration depend manner, the IC <sub>50</sub> values against the Kyse30 and Kyse450 cell lines were all less than 2 μM, presented in a dose-dependent manner. IV-23 triggeres caspases related apoptosis in ESCC cells <sup>[1]</sup> .  IV-23 induces G2/M phase arrest <sup>[1]</sup> .  MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## **REFERENCES**

[1]. Fu DJ, et al. Discovery of indoline derivatives that inhibit esophageal squamous cell carcinoma growth by Noxa mediated apoptosis. Bioorg Chem. 2019 Aug 10;92:103190.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA